Agency / Source: ICL, Inc.

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations - Immunology Consultants Laboratory, Inc. (ICL) has introduced new service offerings to the research and diagnostic community, highlighting expanded capabilities and increased demand for custom solutions - IclLab.com
Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations

 

PRZOOM - /newswire/ - Portland, OR, United States, 2024/05/03 - Immunology Consultants Laboratory, Inc. (ICL) has introduced new service offerings to the research and diagnostic community, highlighting expanded capabilities and increased demand for custom solutions - IclLab.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Immunology Consultants Laboratory, Inc. (ICL) has introduced new service offerings to the research and diagnostic community, highlighting expanded capabilities and increased demand for custom solutions.

Marked by a company-wide rebrand, ICL has shifted focus toward a broader spectrum of biotech pain points, ranging from supply chain consistency to atypical protein expression. New brand elements such as logos and colors have been added to the company’s website and social media presence, representing an aesthetic and procedural change toward the modernization of operations.

ICL has made several high impact staffing decisions, which have improved the reach of communications and the efficacy of collaboration. Research and development efforts have also increased at the company’s Portland headquarters, with plans in place to bolster offerings even further upon collaboration with affiliates.

“By investing more in R&D, we’re able to better support research that’s transforming the health outcomes for a thriving and resilient global community,” says ICL President John Leslie. “We're seeing the needs of the diagnostic industry evolve, and ICL aims to foster a culture of collaboration that drives innovation and empowers our customers and partners through this evolution.”

ICL was founded in 1977 by Gerrie Leslie, a notable figure in the industry for his contributions as the first scientist to characterize the IgY protein, commonly found in egg yolks. Since then, ICL has pioneered some of the industry's first commercialized immunoassay kits, such as ELISA kits designed to detect impurities in specific CHO host cell proteins.

About ICL

ICL (icllab.com) is a U.S.-based manufacturer of biochemical reagents and life science products. With over 45 years in the biotech industry, ICL has developed a strong presence among the world’s leading research institutions, in vitro diagnostics (IVD) manufacturers, and biopharma companies. Offering in-house research and development, ICL also provides custom solutions to research teams and IVD companies whose needs go beyond the industry standard.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: ICL, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Immunology Consultants Laboratory Rebrand Highlights R&D and Service Specializations

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Ryan Negrini - IclLab.com 
503-747-2454 sales[.]icllab.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any ICL, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From ICL, Inc. / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera
JFCR, NEC, and Taiho to Develop Cancer Vaccines Utilizing Whole-Genome Information
Ono Receives Supplemental Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer
Frost Radar™ Identifies Top Growth and Innovation Leaders in Pharmaceutical and Biotech Laboratory Information Management Systems
Ono Submits an Application for Approval of Cenobamate (ONO-2017), Antiseizure Medications in Japan
Viva Biotech Receives Frost & Sullivan’s 2025 APAC Technology Innovation Leadership Recognition in the Integrated Intelligent Drug Discovery Industry
Biotech Firm 4Dcell Selected to Showcase Next-Gen Cardiac Drug Testing Platform At EIC Corporate Day
Deciphera Receives European Commission Approval of ROMVIMZA™ (vimseltinib) for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
Ono and Bristol-Myers Squibb KK Receive Supplemental Approval of Opdivo and Yervoy in Combination Therapy in Japan

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  JobsWare.com

Visit  BizJobs.com

Visit  Limelon Advertising, Co.







 
  ©2005-2025 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today